Novel ranking system for identifying efficacious anti-influenza virus PB2 inhibitors

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 10, 2015, Pages 6007-6016

  Tsai, Alice W ^a   McNeil, Colleen F ^a   Leeman, Joshua R ^a   Bennett, Hamilton B ^a   Nti Addae, Kwame ^a   Huang, Cassey ^a   Germann, Ursula A ^b   Byrn, Randal A ^a   Berlioz Seux, Francoise ^a   Rijnbrand, Rene ^a   Clark, Michael P ^a   Charifson, Paul S ^a   Jones, Steven M ^a  

^a VERTEX PHARMACEUTICALS   (United States)

^b Kognos Scientific Consulting and Services   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; INFLUENZA A VIRUS PB2 PROTEIN; INFLUENZA VIRUS PB2 INHIBITOR; OSELTAMIVIR; SIALIDASE INHIBITOR; UNCLASSIFIED DRUG; VIRUS PROTEIN; HETEROCYCLIC COMPOUND; INDOLE DERIVATIVE; PB2 PROTEIN, INFLUENZA VIRUS; VIRAL PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL THERAPY; ARTICLE; AVIAN INFLUENZA VIRUS; BLOOD SAMPLING; BODY PLETHYSMOGRAPHY; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG IDENTIFICATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; INFLUENZA A; INFLUENZA A VIRUS (H1N1); INFLUENZA A VIRUS (H5N1); INFLUENZA A VIRUS (H7N9); LUNG FUNCTION; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PILOT STUDY; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY; VIRUS LOAD; WEIGHT REDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; ANTIVIRAL RESISTANCE; BAGG ALBINO MOUSE; DRUG EFFECTS; GENE EXPRESSION; GENETICS; LUNG; LUNG FUNCTION TEST; METABOLISM; METHODOLOGY; MORTALITY; ORTHOMYXOVIRIDAE INFECTIONS; PATHOLOGY; PRECLINICAL STUDY; SURVIVAL ANALYSIS; SYNTHESIS; VIROLOGY;

ANIMALS; ANTIVIRAL AGENTS; AZA COMPOUNDS; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, VIRAL; GENE EXPRESSION; INDOLES; INFLUENZA A VIRUS, H1N1 SUBTYPE; LUNG; MALE; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; OSELTAMIVIR; RESEARCH DESIGN; RESPIRATORY FUNCTION TESTS; SURVIVAL ANALYSIS; VIRAL PROTEINS;

EID: 84942891451     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00781-15     Document Type: Article

References (34)

1. Hayden F. 2009. Developing new antiviral agents for influenza treatment: what does the future hold? Clin Infect Dis 48(Suppl 1):S3-S13. http://dx.doi.org/10.1086/591851.
2. Boltz DA, Aldridge JR, Jr, Webster RG, Govorkova EA. 2010. Drugs in development for influenza. Drugs 70:1349-1362. http://dx.doi.org/10.2165/11537960-000000000-00000.
3. Furuta Y, Takahashi K, Fukuda Y, Kuno M, Kamiyama T, Kozaki K, Nomura N, Egawa H, Minami S, Watanabe Y, Narita H, Shiraki K. 2002. In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob Agents Chemother 46:977-981. http://dx.doi.org/10.1128/AAC.46.4.977-981.2002.
4. Furuta Y, Takahashi K, Shiraki K, Sakamoto K, Smee DF, Barnard DL, Gowen BB, Julander JG, Morrey JD. 2009. T-705 (favipiravir) and related compounds: novel broad-spectrum inhibitors of RNA viral infections. Antiviral Res 82:95-102. http://dx.doi.org/10.1016/j.antiviral.2009.02.198.
5. Kiso M, Takahashi K, Sakai-Tagawa Y, Shinya K, Sakabe S, Le QM, Ozawa M, Furuta Y, Kawaoka Y. 2010. T-705 (favipiravir) activity against lethal H5N1 influenza A viruses. Proc Natl Acad Sci U S A 107:882-887. http://dx.doi.org/10.1073/pnas.0909603107.
6. Sidwell RW, Barnard DL, Day CW, Smee DF, Bailey KW, Wong MH, Morrey JD, Furuta Y. 2007. Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice. Antimicrob Agents Chemother 51:845-851. http://dx.doi.org/10.1128/AAC.01051-06.
7. Smee DF, Hurst BL, Wong MH, Bailey KW, Tarbet EB, Morrey JD, Furuta Y. 2010. Effects of the combination of favipiravir (T-705) and oseltamivir on influenza A virus infections in mice. Antimicrob Agents Chemother 54:126-133. http://dx.doi.org/10.1128/AAC.00933-09.
8. Byrn RA, Jones SM, Bennett HB, Bral C, Clark MP, Jacobs MD, Kwong AD, Ledeboer MW, Leeman JR, McNeil CF, Murcko MA, Nezami A, Perola E, Rijnbrand R, Saxena K, Tsai AW, Zhou Y, Charifson PS. 2015. Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunit. Antimicrob Agents Chemother 59:1569-1582. http://dx.doi.org/10.1128/AAC.04623-14.
9. Clark MP, Ledeboer MW, Davies I, Byrn RA, Jones SM, Perola E, Tsai A, Jacobs M, Nti-Addae K, Bandarage UK, Boyd MJ, Bethiel RS, Court JJ, Deng H, Duffy JP, Dorsch WA, Farmer LJ, Gao H, Gu W, Jackson K, Jacobs DH, Kennedy JM, Ledford B, Liang J, Maltais F, Murcko M, Wang T, Wannamaker MW, Bennett HB, Leeman JR, McNeil C, Taylor WP, Memmott C, Jiang M, Rijnbrand R, Bral C, Germann U, Nezami A, Zhang Y, Salituro FG, Bennani YL, Charifson PS. 2014. Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2. J Med Chem 57:6668-6678. http://dx.doi.org/10.1021/jm5007275.
10. Guilligay D, Tarendeau F, Resa-Infante P, Coloma R, Crepin T, Sehr P, Lewis J, Ruigrok RW, Ortin J, Hart DJ, Cusack S. 2008. The structural basis for cap binding by influenza virus polymerase subunit PB2. Nat Struct Mol Biol 15:500-506. http://dx.doi.org/10.1038/nsmb.1421.
11. Sagong HY, Bauman JD, Patel D, Das K, Arnold E, LaVoie EJ. 2014. Phenyl substituted 4-hydroxypyridazin-3 (2H)-ones and 5-hydroxypyrimidin-4 (3H)-ones: inhibitors of influenza A endonuclease. J Med Chem 57:8086-8098. http://dx.doi.org/10.1021/jm500958x.
12. Kowalinski E, Zubieta C, Wolkerstorfer A, Szolar OH, Ruigrok RW, Cusack S. 2012. Structural analysis of specific metal chelating inhibitor binding to the endonuclease domain of influenza pH1N1 (2009) polymerase. PLoS Pathog 8:e1002831. http://dx.doi.org/10.1371/journal.ppat.1002831.
13. DuBois RM, Slavish PJ, Baughman BM, Yun MK, Bao J, Webby RJ, Webb TR, White SW. 2012. Structural and biochemical basis for development of influenza virus inhibitors targeting the PA endonuclease. PLoS Pathog 8:e1002830. http://dx.doi.org/10.1371/journal.ppat.1002830.
14. Muratore G, Goracci L, Mercorelli B, Foeglein A, Digard P, Cruciani G, Palu G, Loregian A. 2012. Small molecule inhibitors of influenza A and B viruses that act by disrupting subunit interactions of the viral polymerase. Proc Natl Acad Sci U S A 109:6247-6252. http://dx.doi.org/10.1073/pnas.1119817109.
15. Sidwell RW, Smee DF. 2000. In vitro and in vivo assay systems for study of influenza virus inhibitors. Antiviral Res 48:1-16. http://dx.doi.org/10.1016/S0166-3542 (00) 00125-X.
16. Hanson BJ, Boon AC, Lim AP, Webb A, Ooi EE, Webby RJ. 2006. Passive immunoprophylaxis and therapy with humanized monoclonal antibody specific for influenza A H5 hemagglutinin in mice. Respir Res 7:126. http://dx.doi.org/10.1186/1465-9921-7-126.
17. Fukushi M, Ito T, Oka T, Kitazawa T, Miyoshi-Akiyama T, Kirikae T, Yamashita M, Kudo K. 2011. Serial histopathological examination of the lungs of mice infected with influenza A virus PR8 strain. PLoS One 6:e21207. http://dx.doi.org/10.1371/journal.pone.0021207.
18. Sanders CJ, Vogel P, McClaren JL, Bajracharya R, Doherty PC, Thomas PG. 2013. Compromised respiratory function in lethal influenza infection is characterized by the depletion of type I alveolar epithelial cells beyond threshold levels. Am J Physiol Lung Cell Mol Physiol 304:L481-L488. http://dx.doi.org/10.1152/ajplung.00343.2012.
19. Julander JG, Hagloch J, Latimer S, Motter N, Dagley A, Barnard DL, Smee DF, Morrey JD. 2011. Use of plethysmography in assessing the efficacy of antivirals in a mouse model of pandemic influenza A virus. Antiviral Res 92:228-236. http://dx.doi.org/10.1016/j.antiviral.2011.08.011.
20. Le Goffic R, Balloy V, Lagranderie M, Alexopoulou L, Escriou N, Flavell R, Chignard M, Si-Tahar M. 2006. Detrimental contribution of the Toll-like receptor (TLR) 3 to influenza A virus-induced acute pneumonia. PLoS Pathog 2:e53. http://dx.doi.org/10.1371/journal.ppat.0020053.
21. Chan J, Nirwati H, Triasih R, Bogdanovic-Sakran N, Soenarto Y, Hakimi M, Duke T, Buttery JP, Bines JE, Bishop RF, Kirkwood CD, Danchin MD. 2011. Maternal antibodies to rotavirus: could they interfere with live rotavirus vaccines in developing countries? Vaccine 29:1242-1247. http://dx.doi.org/10.1016/j.vaccine.2010.11.087.
22. Drusano GL, Preston SL, Smee D, Bush K, Bailey K, Sidwell RW. 2001. Pharmacodynamic evaluation of RWJ-270201, a novel neuraminidase inhibitor, in a lethal murine model of influenza predicts efficacy for oncedaily dosing. Antimicrob Agents Chemother 45:2115-2118. http://dx.doi.org/10.1128/AAC.45.7.2115-2118.2001.
23. McSharry JJ, McDonough AC, Olson BA, Drusano GL. 2004. Phenotypic drug susceptibility assay for influenza virus neuraminidase inhibitors. Clin Diagn Lab Immunol 11:21-28. http://dx.doi.org/10.1128/CDLI.11.1.21-28.2004.
24. Julander JG, Kesler K, Van Wettere AJ, Morrey JD, Smee DF. 2014. The use of plethysmography in determining the severity of lung pathology in a mouse model of minimally lethal influenza virus infection. Antiviral Res 108:10-13. http://dx.doi.org/10.1016/j.antiviral.2014.05.002.
25. Trias EL, Hassantoufighi A, Prince GA, Eichelberger MC. 2009. Comparison of airway measurements during influenza-induced tachypnea in infant and adult cotton rats. BMC Pulm Med 9:28. http://dx.doi.org/10.1186/1471-2466-9-28.
26. WHO. 2002. WHO manual on animal influenza diagnosis and surveillance. WHO, Geneva, Switzerland.
27. Noah JW, Severson W, Noah DL, Rasmussen L, White EL, Jonsson CB. 2007. A cell-based luminescence assay is effective for high-throughput screening of potential influenza antivirals. Antiviral Res 73:50-59. http://dx.doi.org/10.1016/j.antiviral.2006.07.006.
28. Bouvier NM, Lowen AC. 2010. Animal models for influenza virus pathogenesis and transmission. Viruses 2:1530-1563. http://dx.doi.org/10.3390/v20801530.
29. Govorkova EA, Leneva IA, Goloubeva OG, Bush K, Webster RG. 2001. Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses. Antimicrob Agents Chemother 45:2723-2732. http://dx.doi.org/10.1128/AAC.45.10.2723-2732.2001.
30. Leneva IA, Roberts N, Govorkova EA, Goloubeva OG, Webster RG. 2000. The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses. Antiviral Res 48:101-115. http://dx.doi.org/10.1016/S0166-3542 (00) 00123-6.
31. Mendel DB, Tai CY, Escarpe PA, Li W, Sidwell RW, Huffman JH, Sweet C, Jakeman KJ, Merson J, Lacy SA, Lew W, Williams MA, Zhang L, Chen MS, Bischofberger N, Kim CU. 1998. Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection. Antimicrob Agents Chemother 42:640-646.
32. Sidwell RW, Smee DF, Huffman JH, Barnard DL, Bailey KW, Morrey JD, Babu YS. 2001. In vivo influenza virus-inhibitory effects of the cyclopentane neuraminidase inhibitor RJW-270201. Antimicrob Agents Chemother 45:749-757. http://dx.doi.org/10.1128/AAC.45.3.749-757.2001.
33. Anh DB, Faisca P, Desmecht DJ. 2006. Differential resistance/susceptibility patterns to pneumovirus infection among inbred mouse strains. Am J Physiol Lung Cell Mol Physiol 291:L426-L435. http://dx.doi.org/10.1152/ajplung.00483.2005.
34. Mejias A, Chavez-Bueno S, Rios AM, Saavedra-Lozano J, Fonseca Aten M, Hatfield J, Kapur P, Gomez AM, Jafri HS, Ramilo O. 2004. Antirespiratory syncytial virus (RSV) neutralizing antibody decreases lung inflammation, airway obstruction, and airway hyperresponsiveness in a murine RSV model. Antimicrob Agents Chemother 48:1811-1822. http://dx.doi.org/10.1128/AAC.48.5.1811-1822.2004.